First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary studyYing Liu, Jufeng Wang, Shuning Xu et al.|International Journal of Clinical Oncology|2015Cited by 31
Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II studyXiangrui Meng, Feng Wang, Feng Zhao et al.|European Journal of Cancer|2024Cited by 18